Deoxycorticosterone Test

If your blood pressure runs high and your potassium runs low, the usual suspect is aldosterone, the body's primary salt-retaining hormone. But there is a lesser-known hormone in the same pathway that can cause identical problems: deoxycorticosterone, or DOC (11-deoxycorticosterone). When DOC is overproduced, whether by a genetic enzyme defect, a rare adrenal tumor, or abnormal adrenal gland growth, it drives the kidneys to hold onto sodium and dump potassium, raising blood pressure in ways that routine testing can miss entirely.

What makes DOC tricky is that standard workups for hormone-driven high blood pressure focus on aldosterone and renin. If aldosterone comes back normal or low, many clinicians stop looking. But DOC itself has salt-retaining activity, and when it builds up, it suppresses both renin and aldosterone. The result is a patient with all the hallmarks of excess salt-retaining hormone but normal aldosterone, a pattern that can go undiagnosed for years. The median time from symptom onset to diagnosis in DOC-producing adrenal growths is 24 months.

Where DOC Comes From

DOC is made in the adrenal glands, the small hormone-producing organs that sit on top of each kidney. Specifically, it is produced in two zones of the adrenal cortex (the outer layer of the adrenal gland): the zona fasciculata, which responds to ACTH (a pituitary hormone that tells the adrenals to produce stress hormones), and the zona glomerulosa, which responds to the renin-angiotensin system (the body's blood pressure regulation circuit). Under normal conditions, DOC is just a brief pit stop in the hormone assembly line: the enzyme 21-hydroxylase converts progesterone into DOC, then another enzyme called 11-beta-hydroxylase converts DOC into corticosterone, which can eventually become aldosterone.

Normal production is modest, roughly 66 micrograms per day. The kidney itself can also make small amounts of DOC from circulating progesterone, potentially allowing salt-retaining hormone production right at the site where it acts. Under normal circumstances, DOC contributes only a small fraction of your total salt-retaining hormone activity. The problems start when an enzyme blockage or a tumor causes DOC to accumulate instead of being converted to the next hormone in the chain.

Congenital Adrenal Hyperplasia and DOC Excess

The most well-characterized cause of elevated DOC is a group of inherited enzyme deficiencies collectively called congenital adrenal hyperplasia (CAH). Two specific enzyme defects cause DOC to build up, each with a distinct clinical picture.

In 11-beta-hydroxylase deficiency, the enzyme that converts DOC into the next hormone (corticosterone) is impaired. DOC accumulates and acts on the kidneys to retain sodium and excrete potassium, causing high blood pressure and low potassium. Because cortisol production is also impaired, the pituitary gland pumps out extra ACTH, which pushes the adrenals even harder, creating more DOC. Patients often also develop excess androgen production (virilization). In 17-alpha-hydroxylase deficiency, steroid production is shunted away from the cortisol and sex hormone pathways and toward DOC. These patients develop high blood pressure with low potassium but also have underdeveloped sex characteristics because of absent sex hormone production.

DOC-Producing Tumors

Adrenal tumors that produce DOC are rare but serious. A systematic review found that adrenal cancers (carcinomas) are the most common type, making up about 45.7% of DOC-producing tumors, typically affecting middle-aged women. Malignant tumors tend to be larger and produce higher DOC levels than benign ones (adenomas). In one analysis, the median DOC level in tumor patients was 12.5 times above normal.

The clinical presentation mirrors other forms of salt-retaining hormone excess: resistant high blood pressure, low potassium, and suppressed renin. The distinguishing feature is that aldosterone is low or normal. This is the key clue that should trigger DOC measurement. If a clinician measures only aldosterone and finds it low, they may dismiss a hormonal cause for hypertension altogether, missing the tumor.

High Blood Pressure Without an Obvious Cause

Some researchers have investigated whether subtle DOC excess might explain a subset of essential hypertension (high blood pressure with no identified cause), particularly in patients with low renin levels. However, studies specifically testing this hypothesis have failed to demonstrate elevated DOC in low-renin essential hypertension compared to normal controls. A related finding is that 22% to 37% of hypertensive patients have elevated levels of 18-hydroxy-DOC (a close metabolite), with mean levels in normal-renin essential hypertension reaching 11.6 ng/dL compared to 5.4 ng/dL in controls. Whether this metabolite plays a direct role in blood pressure remains an open question.

Racial and Ethnic Differences

One study comparing Black and white individuals found that Black participants had lower baseline DOC levels (247 vs. 381 pmol/L) and lower DOC after ACTH stimulation (822 vs. 1,127 pmol/L at 30 minutes). This finding challenges the older hypothesis that increased sodium retention in Black populations might be driven by higher salt-retaining hormone production. The evidence points instead toward other mechanisms for the observed differences in salt sensitivity and blood pressure.

Reference Ranges

DOC reference ranges vary by assay method, and modern techniques using mass spectrometry (LC-MS/MS) give more accurate results than older antibody-based methods. The values below are drawn from published research on healthy adults and represent morning blood draws.

Men generally have higher DOC levels than women. In children, levels are elevated in newborns (average around 4.1 ng/dL), drop during infancy, and remain relatively stable through childhood until puberty. In older men, DOC production rates decline, falling from about 0.089 mg/day in younger men to about 0.047 mg/day in elderly men. BMI has a weak inverse relationship with DOC after correcting for age and sex. Women show higher DOC in the luteal phase of the menstrual cycle (the two weeks before a period) due to ovarian progesterone conversion.

These ranges are drawn from published research. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. There are no established "optimal" DOC levels from a preventive health or longevity perspective. DOC is measured to diagnose specific adrenal disorders, not to optimize a target number.

When Results Can Be Misleading

DOC has a pronounced daily rhythm, peaking around 8 AM and falling to its lowest point at midnight. A blood draw at the wrong time of day can produce a value that looks normal when it isn't, or elevated when it's actually fine. Always draw in the morning after being upright for at least two hours and seated for five to fifteen minutes.

Women's DOC levels fluctuate with the menstrual cycle, running higher in the luteal phase. If you are premenopausal, the timing of your blood draw relative to your cycle matters, and your clinician should document which phase you are in.

Several medications can shift DOC without causing the adrenal disease that DOC testing is designed to detect. Spironolactone (a common blood pressure medication) genuinely raises DOC by partially blocking enzymes in the aldosterone production pathway. At 400 mg/day, significant DOC increases appear by day 10. Older lab assays could also show falsely elevated DOC due to cross-reactivity with canrenone, a spironolactone metabolite, so the method matters. Dexamethasone suppresses DOC to very low levels within three days by shutting down ACTH. Metyrapone, used in diagnostic testing for adrenal function, can drive DOC up roughly 25-fold within 24 hours. If you are taking any of these medications, your clinician needs to account for their effects when reading your results.

Acute stress, surgery, and illness activate the pituitary-adrenal stress response, raising ACTH and therefore DOC. Surgical stress can sustain elevated DOC for several days after the procedure. If you have recently been ill or had surgery, wait at least a week before testing for a reliable baseline reading.

Tracking Your Trend

A single DOC measurement is a snapshot taken under one set of conditions. Analytical variability for DOC assays runs between 8% and 17% depending on the method, and the biological variation of related adrenal steroids (how much your own levels naturally fluctuate day to day) is typically in the 11% to 23% range. Combining these two sources of variation, a change of roughly 40% to 60% between two readings is needed before you can be confident the change is real rather than noise.

If you are being evaluated for a DOC-related disorder or monitoring treatment for CAH, standardize every draw: same time of morning, same posture (seated after being upright), same menstrual cycle phase if applicable, and the same lab using the same assay. Document any medications, especially spironolactone, corticosteroids, or oral contraceptives. If your initial result is borderline or unexpected, retest under identical conditions before drawing conclusions. For ongoing monitoring, your clinician will set an interval based on your specific condition, but tracking at least two to three readings under consistent conditions gives a far more reliable picture than any single number.